Mode
Text Size
Log in / Sign up
N/A N=15 Treatment

Multicenter Trial of Magnetic Mini-Mover for Pectus Excavatum

Pectus Excavatum

Enrolled (actual)
15
Serious AEs
13.3%
Results posted
May 2018
Primary outcome: Primary: Number of Participants With Adverse Reactions — 13; 15; 14; 8 Participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Magnetic Mini-Mover Procedure (Magnimplant) (Device)
Age
Pediatric · 8+ yrs
Sex
All
Sponsor
Michael Harrison
Primary completion
Nov 2016

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants With Adverse Reactions
13; 15; 14; 8
SECONDARY
Comfort and Brace Wear During Treatment
5; 10
SECONDARY
Chest Wall Correction, by Pectus Severity Index
5; 2; 7 0.486
SECONDARY
Patient Satisfaction During the Treatment
11; 11; 9; 8

Summary

This study is a Phase 3, multicenter, non-randomized study to evaluate the safety and efficacy of the next-generation outpatient Magnetic Mini-Mover Procedure (3MP) in 15 patients aged 8-14 years for the correction of pectus excavatum ('sunken chest'). 3MP for pectus excavatum uses a magnetically coupled implant to pull the sternum forward and gradually remodel the deformed costal cartilage. The Funding Source for this trial is the FDA Office of Orphan Products Development (Grant #R01 FD003341).

Eligibility Criteria

Inclusion Criteria

  • Otherwise healthy male or female with pectus excavatum deformity
  • Between 8 and 14 years of age (inclusive)
  • Pectus Severity Index > 3.5 (normal 2.56). NOTE: A pectus severity index of 3.5 or greater qualifies as a moderate-to-severe deformity, and justifies operative intervention
  • Ability to read, speak and understand English
  • Onset of rapid growth of puberty documented by hand/wrist x-ray in early to mid-puberty (defined as bone age in females of 7-13 years, and males of 9-14 years)

Exclusion Criteria

  • Other congenital anomalies (including significant skeletal anomalies such as scoliosis, bony fusion involving the cervical vertebrae) not directly related to pectus excavatum
  • Bleeding disorders
  • Heart disease (including arrhythmia)
  • Persons with active implantable medical devices (AIMD) such as pacemakers
  • Persons with a relative(s) or close family friend(s) living within their households and having a pacemaker
  • Persons with arteriovenous malformations
  • Chest deformity more complicated than pectus excavatum (e.g., Poland syndrome)
  • Persons for whom a foreign body implant would pose a risk (e.g., immunodeficiency)
  • Persons at increased risk for general anesthesia (e.g., history of malignant hyperthermia)
  • Respiratory conditions that have required steroid treatment (e.g., prednisone) in the last 3 years
  • Pregnancy
  • Inability to understand or follow instructions
  • Refusal to wear the external brace
  • Refusal to undergo monthly chest x-rays
  • Inability or refusal to return to UCSF for biweekly follow-up visits for the first month after surgery, and monthly thereafter until explant.
  • Inability to obtain pre-approval (authorization) from the patient's insurance carrier
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01327274). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search